Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
Sara Alosaimy, Sarah C J Jorgensen, Abdalhamid M Lagnf, Sarah Melvin, Ryan P. Mynatt, Travis J Carlson, Kevin W. Garey, David W. Allen, Veena Venugopalan, Michael P. Veve, Vasilios Athans, Stephen Saw, Christine Yost, Susan L. Davis, Michael J. Rybak
Abstract
Abstract Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.
Topics & Concepts
MedicineMeropenemGramRashEnterobacteriaceaeGram-negative bacterial infectionsCarbapenemInternal medicineMicrobiologyAntibioticsAntibiotic resistanceBacteriaEscherichia coliBiologyGeneticsGeneBiochemistryAntibiotics Pharmacokinetics and EfficacyAntibiotic Resistance in BacteriaAntibiotic Use and Resistance